STOCK TITAN

Morphosys AG - MOR STOCK NEWS

Welcome to our dedicated news page for Morphosys (Ticker: MOR), a resource for investors and traders seeking the latest updates and insights on Morphosys.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphosys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphosys's position in the market.

Rhea-AI Summary
MorphoSys AG (MOR) announced strong topline results from the Phase 3 MANIFEST-2 study, showing pelabresib's significant improvement in myelofibrosis patients. The combination therapy met the primary endpoint, nearly doubling SVR35 response rate, and demonstrated meaningful anemia improvement. Key secondary endpoints assessing symptom reduction and TSS showed significant improvements for intermediate-risk patients. Safety results were consistent with prior clinical trials. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.35%
Tags
-
Rhea-AI Summary
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports Q3 2023 results, including Monjuvi U.S. net product sales of US$ 23.4 million. Phase 3 MANIFEST-2 topline results expected by end of November, with detailed findings in oral presentation at ASH 2023. U.S. FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer. Company has € 642.2 million in cash and other financial assets as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.79%
Tags
-
Rhea-AI Summary
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will release its Q3 and first nine months 2023 results on November 15, 2023, with a conference call and webcast on November 16, 2023. The Management team will present the results and outlook, followed by a Q&A session. Participants can join via phone or webcast, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
Rhea-AI Summary
MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib will be presented at the ASH Annual Meeting. The trial evaluated the investigational BET inhibitor in combination with the JAK inhibitor ruxolitinib in myelofibrosis patients. The company will also share topline results from the study in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
-
Rhea-AI Summary
MorphoSys reports preliminary Q3 2023 net product sales of $23.4 million for Monjuvi in the US. Full year 2023 sales expected to be $85-95 million with a gross margin of approximately 75%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Summary
MorphoSys AG's tulmimetostat receives Fast Track designation from FDA for the treatment of endometrial cancer with ARID1A mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
Morphosys AG

Nasdaq:MOR

MOR Rankings

MOR Stock Data

2.74B
33.15M
15.97%
1.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Planegg

About MOR

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.